Research Article

Comparison of oocyte maturity rates in recombinant Human Chorionic Gonadotropin (HCG) and triptorelin acetate triggers: A prospective randomized study

Lakshmanan S, Saravanan M, Senthil P* and Sharma N

Published: 13 October, 2020 | Volume 3 - Issue 2 | Pages: 123-126

Luteinizing Hormone (LH) like exposure in the mid cycle for inducing the oocyte maturation is the very crucial step in the success of ICSI treatment. Introduction of LH surge endogenously by GnRH-agonist for final oocyte maturation induction, may be more physiological compared with the administration of HCG. Since GnRH agonist would induce FSH surge also along with LH surge, as happens in natural cycle. However, the effects of giving HCG trigger for inducing only LH surge and giving GnRH agonist trigger for inducing both LH and FSH surge, in patients treated for ICSI with GnRH antagonists need more research. Sub fertile patients planned for ICSI, meeting the requirement of inclusion criteria, were started with recombinant FSH from day 2 of menstrual cycle. GnRH antagonists were started from day 6 of stimulation. FSH dose was adjusted according to the individual response. Trigger was planned when the lead follicle reaches 24 mm. For triggering, 100 patients were randomized to receive Recombinant HCG trigger and Triptorelin acetate trigger. Oocyte retrieval was done 36 hours after Recombinant hCG Trigger and 35 hours after Triptorelin acetate trigger. The oocyte maturity rate was assessed by the number of metaphase II oocytes retrieved.

Read Full Article HTML DOI: 10.29328/journal.cjog.1001064 Cite this Article Read Full Article PDF


GnRH agonist trigger; GnRH antagonist cycle; Metaphase 2 oocytes; Oocyte maturation rate; Recombinant hCG Trigger; Triptorelin acetate trigger


  1. World Health Organization. Prevalence of moderate and severe disability (in millions), by leading health condition associated with disability, and by age and income status of countries.
  2. Shoham Z, Schacter M, Loumaye E, Weissman A, MacNamee M, et al. The luteinizing hormonesurge—the final stage in ovulation induction: modern aspects of ovulation triggering. Fertil Steril.1995; 64: 237–251. PubMed: https://pubmed.ncbi.nlm.nih.gov/7615097/
  3. Voronina E, Wessel G. The regulation of oocyte maturation. Curr Top Dev Biol. 2003; 58: 53–110. PubMed: https://pubmed.ncbi.nlm.nih.gov/14711013/
  4. Cheung LP, Lam PM, Lok IH, Chiu TT, Yeung SY, et al. GnRH antagonist versus long GnRH agonist protocol in poor responders undergoing IVF: a randomized controlled trial. Hum Reprod. 20: 616-621. PubMed: https://pubmed.ncbi.nlm.nih.gov/15608037/
  5. Huirne JA, Homburg R and Lambalk CB. Are GnRH antagonists comparable to agonists for use in IVF? Hum Reprod. 2007. 22: 2805-2813. PubMed: https://pubmed.ncbi.nlm.nih.gov/17872909/
  6. Olivennes F, Belaisch-Allart J, Emperaire JC, Dechaud H, Alvarez S, et al. Prospective, randomized, controlled study of in vitro fertilization-embryo transfer with a single dose of a luteinizing hormone-releasing hormone (LH-RH) antagonist (cetrorelix) or a depot formula of an LH-RH agonist (triptorelin). Fertil Steril. 2000; 73: 314-320. PubMed: https://pubmed.ncbi.nlm.nih.gov/10685535/
  7. Humaidan P, Polyzos N, Alsbjerg B, Erb K, Mikkelsen A, et al. GnRHa trigger and individualized luteal phase hCG support according to ovarian response to stimulation: two prospective randomized controlled multi-center studies in IVF patients. Hum Reprod. 2013; 28: 2511–2521. PubMed: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5054292/
  8. Reddy J, Turan V, Bedoschi G, Moy F, Oktay K. Triggering final oocyte maturation with gonadotropin-releasing hormone agonist (GnRHa) versus human chorionic gonadotropin (hCG) in breast cancer patients undergoing fertility preservation: an extended experience. J Assist Reprod Genet. 2014; 31: 927–932. PubMed: https://pubmed.ncbi.nlm.nih.gov/24854484/
  9. Richards JS, Hernandez-Gonzalez I, Gonzalez-Robayna I, Teuling E, Lo Y, et al. Regulated expression of ADAMTS family members in follicles and cumulus oocyte complexes: evidence for specific and redundant patterns during ovulation. Biol Reprod. 2005; 72: 1241–1255.
  10. Lamb JD, Shen S, McCulloch C, Jalalian L, Cedars MI, et al. Follicle-stimulating hormone administered at the time of human chorionic gonadotropin trigger improves oocyte developmental competence in in vitro fertilization cycles: a randomized, double-blind, placebo-controlled trial. Fertil Steril. 2011; 95: 1655–1660. PubMed: https://pubmed.ncbi.nlm.nih.gov/21315341/
  11. Andersen CY, Leonardsen L, Ulloa-Aguirre A, Barrios-De-Tomasi J, Moore L, et al. FSH-induced resumption of meiosis in mouse oocytes: effect of different isoforms. Mol Hum Reprod.1999; 5: 726–731.
  12. Shapiro BS, Andersen CY. Major drawbacks and additional benefits of agonist trigger-not ovarian hyper stimulation syndrome related. Fertil Steril. 2015; 103: 874–878. PubMed: https://pubmed.ncbi.nlm.nih.gov/25707333/
  13. Gonen Y, Balakier H, Powell W, Casper RF. Use ofgonadotropin-releasing hormone agonist to trigger follicular maturation for in vitro fertilization. J ClinEndocrinol Metab. 1990; 71: 918–922. PubMed: https://pubmed.ncbi.nlm.nih.gov/2119392/
  14. Andersen CY, Humaidan P, Ejdrup HB, Bungum L, Grøndahl ML, et al. Hormonal characteristics of follicular fluid from women receiving either GnRH agonist or hCG for ovulation induction. Hum Reprod. 2006; 21: 2126-2130. PubMed: https://pubmed.ncbi.nlm.nih.gov/16682403/
  15. Humaidan P, Westergaard LG, Mikkelsen AL, Fukuda M, Yding Andersen C. Levels of the epidermal growthfactor-like peptide amphiregulin in follicular fluid reflect the mode of triggering ovulation: a comparison between gonadotrophin-releasing hormone agonist and urinary human chorionic gonadotrophin. Fertil Steril. 2011b; 95: 2034-2038. PubMed: https://pubmed.ncbi.nlm.nih.gov/21377153/
  16. Mascarenhas MN, Flaxman SR, Boerma T, Vanderpoel S, Stevens GA. National, regional, andglobal trends in infertility prevalence since 1990:a systematic analysis of 277 health surveys. PLoSMed. 2012; 9: e1001356. PubMed: https://pubmed.ncbi.nlm.nih.gov/23271957/


Figure 1

Figure 1

Similar Articles

Recently Viewed

  • Effect of laparoscopic salpingectomy on subsequent ovarian response after controlled ovarian hyperstimulation
    Chadi Yazbeck*, Asma Boukadida, Christian Chauvin, Anne Laure Margulies and Ségolène Falcone Chadi Yazbeck*,Asma Boukadida,Christian Chauvin,Anne Laure Margulies,Ségolène Falcone. Effect of laparoscopic salpingectomy on subsequent ovarian response after controlled ovarian hyperstimulation. Clin J Obstet Gynecol. 2019: doi: 10.29328/journal.cjog.1001030; 2: 107-112
  • Gynaecological malignancies after breast cancer diagnosis: A population-based study
    Maria Pilar Barretina-Ginesta, Jaume Galceran*, Helena Pla, Cristina Meléndez, Anna Carbo Bague, Alberto Ameijide, Marià Carulla, Jordi Barretina, Angel Izquierdo and Rafael Marcos-Gragera Maria Pilar Barretina-Ginesta,Jaume Galceran*,Helena Pla,Cristina Meléndez,Anna Carbo Bague,Alberto Ameijide,Marià Carulla,Jordi Barretina,Angel Izquierdo,Rafael Marcos-Gragera. Gynaecological malignancies after breast cancer diagnosis: A population-based study. Clin J Obstet Gynecol. 2019: doi: 10.29328/journal.cjog.1001031; 2: 113-118
  • First trimester growth delay: An early marker of triploidy
    Sydney M Thayer*, Rachel A Pilliod, Emmanuelle Pare, Amber Vandehey, Hannah Raszka, Kelly Thomas and Rinathia Hachmon Sydney M Thayer*,Rachel A Pilliod,Emmanuelle Pare,Amber Vandehey,Hannah Raszka,Kelly Thomas,Rinathia Hachmon. First trimester growth delay: An early marker of triploidy. Clin J Obstet Gynecol. 2019: doi: 10.29328/journal.cjog.1001032; 2: 119-121
  • Correlation between the presence of maternal gestational or pre-gestational pathologies and hearing impairment in the puerperal period
    Raphaella Costa Moreira Simen*, Alan Araújo Vieira, Maria Elisa Vieira da Cunha Ramos Miterhof and Armanda de Oliveira Pache de Faria Raphaella Costa Moreira Simen*,Alan Araújo Vieira,Maria Elisa Vieira da Cunha Ramos Miterhof,Armanda de Oliveira Pache de Faria. Correlation between the presence of maternal gestational or pre-gestational pathologies and hearing impairment in the puerperal period. Clin J Obstet Gynecol. 2019: doi: 10.29328/journal.cjog.1001033; 2: 122-126
  • Previous antibiotic treatment as a risk factor for recurrent vulvovaginal candidiasis
    Wen Yang#, You Nie#, Shujuan Wang, Hongwei Wang, Enfeng Zhao and Na Dou* Wen Yang#,You Nie#,Shujuan Wang,Hongwei Wang,Enfeng Zhao,Na Dou*. Previous antibiotic treatment as a risk factor for recurrent vulvovaginal candidiasis. Clin J Obstet Gynecol. 2019: doi: 10.29328/journal.cjog.1001034; 2: 127-132

Read More

Most Viewed

Read More

Help ?